Teva Pharmaceutical Industries Limited Provides Update on Generic Evista(R) Litigation

Published: Sep 24, 2009

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA’s Orange Book for Eli Lilly’s Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva’s abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.

Back to news